clinical trial · NCT06891833
A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.·phase3·recruiting·n = 120
HER2-positive Breast CancerBL-M07D1Pertuzumab
brief summary
This trial is a registered phase III, randomized, open and multicenter study to evaluate the efficacy and safety of BL-M07D1 with or without Pertuzumab in the neoadjuvant treatment of HER2-positive breast cancer. The study is divided into a single-arm study phase (Phase II) and a randomized controlled study phase (Phase III).
started
Jun 5, 2025
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Oct 2, 2025
official title
A Randomized Controlled Phase II/III Clinical Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol